Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And it is nice to see that also by industry peer comparison, we are performing very well |
| So truly, a very strong pipeline |
| But, all-in-all, I am very confident that, we are making the desired progress that we do it year-over-year, and that we are not just focusing on the long-term perspective, but have targets for each and every year that hold us accountable to make steady progress, essentially also in the near-term time horizon |
| And if we do this right, and if we do this consistent, then in itself, we are driving a positive impact on society, and that needs to be the focus of all of our operations |
| Next slide please? So, in summary, we are well prepared and well positioned to manage our reporting requirements in the evolving landscape that we face |
| We believe that is one of the highest in our sector |
| I am really very pleased to share with you our malaria portfolio |
| We continue to be proud of our current position and our accomplishments today |
| And then lastly, and Paul alluded to that we are well positioned to meet the existing or emerging ESG reporting requirements |
| So, if I can have the next slide? Just want to reiterate that Novartis is extremely proud of its long-term commitment to Global Health R&D |
| And I hope that there will be sufficient support for those partners in their environment that we continue on that partnership journey, which I find really being very well positioned in order to make an impact at scale |
| We remain confident in our ESG reporting structures that will enable us to continue to deliver high quality and compliant ESG data |
| Reaching more patients with innovative medicines, creating sustainable social and economic impact, and building trust with society |
| Thierry has been leading now the Global Health Research unit previously called Novartis Institute for Tropical Diseases for over 10 years and has truly built up a very robust growth in terms of breadth and depth pipeline |
| But it’s been a very -- I mean, I was very, very -- I would say, impressed by the scale with which we were being able to make this shift |
| I believe the example in Ethiopia showed that long-term commitments and partnerships can drive tremendous benefit |
| And then -- and here I have to give credit specifically to Steffen Lang, our President of Operations that we are making very good progress against the targets that we have set for carbon, for waste and for water |
| We believe we are well positioned and prepared to meet the requirements of these regulatory standards and we’re well prepared to manage our ESG processes, our reporting structures according to the new regulations |
| We are making very good progress on the patient reach target, both with strategic innovative therapies but also with the Global Health’s flagship programs, and are confident that if we project out for the full year, we’ll be reaching those targets that we’ve set for this year |
| Can we move to the next slide, please? So in summary, I hope we’ve impressed upon you that we have quite an extensive innovative global health pipeline, addressing unmet needs in underserved patient populations |
| And we believe by doing our core business very well, doing it consistently and reliably that we are fulfilling unmet needs on the medical front, and that we are able to broaden the benefit of our medicines to as many patients as possible |
| And just through that mindset shift towards this creating impact in Sub-Saharan Africa, we are doing good for society but we are also essentially helping grow the business, which historically has, and this year is expected to outgrow the margin and the GDP growth |
| I’m also pleased with the progress that we continue to make on our Global Health pipeline |
| On human capital, we are also making good progress, and I am very happy to remind everyone that we have renewed our EPIC pledge in September this year, expanding it based on the development that has taken place in this space |
| This will position us well to meet the current and the future ESG reporting requirements, as they evolve and come |
| And through this program, so far, we have been able to reach 2,000 patients who have benefited significantly from this program |
| I was in Ethiopia just a few weeks ago and hadn’t had the opportunity to visit this country for five years and was really impressed with the work that happens at the Black Lion Hospital, which is the largest hospital in Addis Ababa, serving the majority of Ethiopia as a tertiary care facility on chronic myeloid leukemia |
| We’ve had a very strong phenotypic efforts where we discovered actually the precursor to a front runner the NS4B inhibitor, EYU688, which is expected to be in Phase 2 clinical trials very shortly now and really have been able to advance the case of dengue research across the board with partners such as the Wellcome Trust and today, the National Institute of Health in the U.S., which is partnering on some of the follow-up efforts in the dengue space |
| And that worked extremely well |
| This is something that we take great pride in from a leadership team, and I can speak for all of the employees at our company |
| Statement |
|---|
| So, it’s a bit of the opportunity that potentially comes through new technologies, but then it also derail us at global or regional scale that are very difficult to predict |
| There’s been a gap in the national malaria control programs, which have introduced now a really growing problem |
| But it shows that even in high-income countries, we see the number of clinical trials as a driver of innovation to decline, as countries become less and less economically successful |
| And then, as we were planning, we saw that first line treatment, Hydroxyurea is totally out of reach for many patients, but even worse than that that most patients who have the disease aren’t even identified through newborn screening |
| comes with price pressures that have a very significant magnitude |
| But we also understand that we cannot rest, and there are signs that drug resistance to artemisinin, as I mentioned, is becoming a very serious threat |
| It is a known fact that there is a lack of racial diversity in our clinical trials, and ethnic minorities are underrepresented in our clinical trials |
| The second categories are basically drugs that do not -- are poorly effective |
| So, we start by looking at obviously the WHO global health priorities, and they broadly fall in three categories: emerging drug resistance issue, and that’s a very big problem from malaria right now where we’re seeing mutations that confer drug resistance to the first-line therapies, artemisinin combination therapies, which basically are threatening the efficacy of these very important drugs |
| I mean, the world has become very unpredictable |
| Of course, we always regret if we lose a great partner |
| And we will see a comeback in the resurgence of diseases that have disappeared from primarily other geographical regions where the disease were actually not present for a long time |
| We have accomplished this for the last few years, and it really shows that early on, we are serious about access and access cannot be an afterthought after we have launched medicine successfully in high-income countries |
| I think it’s fair to say that our industry is not a stranger to price pressures |
| We need to manage crises |
| So, we really are considering global health challenges to be met just as any other disease areas with the full spectrum of our capabilities at Novartis |
| So, if I can have the next slide? As mentioned several times during the introduction, the unmet needs for neglected tropical disease and global health challenges is massive |
| What would you identify as the main variables that could pose a threat to achieving your long-term targets? And I guess, I would post this question to both you and Klaus |
| And you can see by volume and with that by impact at the patient level, the emerging market brands exceeds those of the originator brands |
| In addition, with this climate change will also affect disease burden worldwide |
Please consider a small donation if you think this website provides you with relevant information